Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.32% | -9.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.00% | -4.78% | |||
| Operating Income | -16.00% | 4.78% | |||
| Income Before Tax | -29.23% | 10.17% | |||
| Income Tax Expenses | 100.00% | 55.56% | |||
| Earnings from Continuing Operations | -29.26% | 10.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 44.68% | -79.91% | |||
| Net Income | -29.25% | 9.94% | |||
| EBIT | -16.00% | 4.78% | |||
| EBITDA | -15.95% | 52.14% | |||
| EPS Basic | -17.64% | 52.25% | |||
| Normalized Basic EPS | -28.49% | 10.04% | |||
| EPS Diluted | -17.64% | 53.12% | |||
| Normalized Diluted EPS | -28.49% | 10.04% | |||
| Average Basic Shares Outstanding | 0.63% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.63% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||